Trial
NCT03689894
Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Dartmouth-Hitchcock Medical Center
Collaborators
—
Condition
Chronic Graft-versus-host-disease
Intervention
Ibrutinib
Why stopped
Insufficient accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-28